drugset / Trial / NCT03574142

A Ph 1 Study of Epanova® in Healthy Chineses

NCT03574142

Phase 1 Completed 14 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to explore the safety, tolerability, and PK of single and multiple doses of Epanova in healthy male and female Chinese subjects and to allow comparison of these parameters with the Western population studied to date.

Timeline

Start
2018-06-04
Primary completion
2018-06-27
Completion
2018-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Epanova Other / unclassified 4 g Oral

Indications

No indication recorded.